Cargando…
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer (GC) are presented. METHODS: Retrospective analysis: Sixty PIPAC were...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722080/ https://www.ncbi.nlm.nih.gov/pubmed/26511950 http://dx.doi.org/10.1007/s11605-015-2995-9 |
_version_ | 1782411316522123264 |
---|---|
author | Nadiradze, Giorgi Giger-Pabst, Urs Zieren, Juergen Strumberg, Dirk Solass, Wiebke Reymond, Marc-André |
author_facet | Nadiradze, Giorgi Giger-Pabst, Urs Zieren, Juergen Strumberg, Dirk Solass, Wiebke Reymond, Marc-André |
author_sort | Nadiradze, Giorgi |
collection | PubMed |
description | BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer (GC) are presented. METHODS: Retrospective analysis: Sixty PIPAC were applied in 24 consecutive patients with PM from GC. 67 % patients had previous surgery, and 79 % previous platinum-based systemic chemotherapy. Mean Peritoneal Carcinomatosis Index (PCI) of 16 ± 10 and 18/24 patients had signet-ring GC. Cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) were given for 30 min at 37 °C and 12 mmHg at 6 week intervals. Outcome criteria were survival, adverse events, and histological tumor response. RESULTS: Median follow-up was 248 days (range 105–748), and median survival time was 15.4 months. Seventeen patients had repeated PIPAC, and objective tumor response was observed in 12 (12/24 = 50 %): no vital tumor cells = 6, major pathological response = 6, minor response = 3. Postoperative adverse events > CTCAE 2 were observed in 9 patients (9/24, 37.5 %). In 3/17 patients, a later PIPAC could not be performed due to non-access. Two patients (ECOG 3 and 4) died in the hospital due to disease progression. CONCLUSION: PIPAC with low-dose cisplatin and doxorubicin was safe and induced objective tumor regression in selected patients with PM from recurrent, platinum-resistant GC. First survival data are encouraging and justify further clinical studies in this indication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11605-015-2995-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4722080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-47220802016-02-01 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis Nadiradze, Giorgi Giger-Pabst, Urs Zieren, Juergen Strumberg, Dirk Solass, Wiebke Reymond, Marc-André J Gastrointest Surg Original Article BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer (GC) are presented. METHODS: Retrospective analysis: Sixty PIPAC were applied in 24 consecutive patients with PM from GC. 67 % patients had previous surgery, and 79 % previous platinum-based systemic chemotherapy. Mean Peritoneal Carcinomatosis Index (PCI) of 16 ± 10 and 18/24 patients had signet-ring GC. Cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) were given for 30 min at 37 °C and 12 mmHg at 6 week intervals. Outcome criteria were survival, adverse events, and histological tumor response. RESULTS: Median follow-up was 248 days (range 105–748), and median survival time was 15.4 months. Seventeen patients had repeated PIPAC, and objective tumor response was observed in 12 (12/24 = 50 %): no vital tumor cells = 6, major pathological response = 6, minor response = 3. Postoperative adverse events > CTCAE 2 were observed in 9 patients (9/24, 37.5 %). In 3/17 patients, a later PIPAC could not be performed due to non-access. Two patients (ECOG 3 and 4) died in the hospital due to disease progression. CONCLUSION: PIPAC with low-dose cisplatin and doxorubicin was safe and induced objective tumor regression in selected patients with PM from recurrent, platinum-resistant GC. First survival data are encouraging and justify further clinical studies in this indication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11605-015-2995-9) contains supplementary material, which is available to authorized users. Springer US 2015-10-28 2016 /pmc/articles/PMC4722080/ /pubmed/26511950 http://dx.doi.org/10.1007/s11605-015-2995-9 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Nadiradze, Giorgi Giger-Pabst, Urs Zieren, Juergen Strumberg, Dirk Solass, Wiebke Reymond, Marc-André Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title_full | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title_fullStr | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title_full_unstemmed | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title_short | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis |
title_sort | pressurized intraperitoneal aerosol chemotherapy (pipac) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722080/ https://www.ncbi.nlm.nih.gov/pubmed/26511950 http://dx.doi.org/10.1007/s11605-015-2995-9 |
work_keys_str_mv | AT nadiradzegiorgi pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis AT gigerpabsturs pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis AT zierenjuergen pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis AT strumbergdirk pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis AT solasswiebke pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis AT reymondmarcandre pressurizedintraperitonealaerosolchemotherapypipacwithlowdosecisplatinanddoxorubiciningastricperitonealmetastasis |